부산대학교 도서관

Purpose The blinq (Rebion Inc) is a new screening device designed to directly detect amblyopia and strabismus rather than amblyopia risk factors. We performed an independent assessment of the effectiveness of the blinq in detecting amblyopia and strabismus. Design Prospective clinical validity analysis of a screening device based on sensitivity and specificity. Methods Children presenting for examination in the pediatric ophthalmology clinic underwent screening with the blinq before examination by a pediatric ophthalmologist blinded to the screening results. Results of the blinq and examination findings of strabismus or amblyopia were compared. Results In our cohort of 267 children with an average age of 6.3 years, the sensitivity of the blinq to detect amblyopia or any constant strabismus was 87.5% (78.2%-93.8%) and specificity was 51.3% (43.9%-58.7%). Using the previously described 'appropriate referral gold standard' criteria, including children with intermittent strabismus and high refractive error, the sensitivity increased to 91.3% and the specificity to 63.2%. We found a high number of children (44 [16%]) upon whom the blinq timed out and were included as automatic referrals. Conclusions Our results support use of the blinq as a screening device to detect amblyopia and strabismus in children. Author Affiliation: From the Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina * Inquiries to Mae Millicent W. Peterseim, Storm Eye Institute, Department of Ophthalmology, Medical University of South Carolina, 167 Ashley Ave, Charleston, SC 29425, USA Article History: Received 24 August 2022; Revised 9 January 2023; Accepted 11 January 2023 Byline: Savannah Reaves Monahan, Samantha M. Smith, Elizabeth Thompson Gammeltoft, Rupal H. Trivedi, M. Edward Wilson, James D. Bowsher, Mae Millicent W. Peterseim [petersem@musc.edu] (*)